Eight Roads

Eight Roads is the global venture and growth investment arm of Fidelity, and the firm operates across the United States, Europe, and Asia with a particular strength at the intersection of healthcare technology, enterprise software, and applied AI. The London office is the firm’s European headquarters and the natural entry point for healthcare AI founders evaluating Eight Roads as a potential partner. The Fidelity heritage matters because it shapes both the firm’s time horizon and its willingness to engage with companies whose path to scale runs longer than the standard ten-year venture vintage. For founders building healthcare AI software at Series A and beyond, Eight Roads is one of a small set of European-anchored firms that can credibly lead competitive rounds against US-based peers.

The investment thesis spans digital health, health IT and healthcare software, medical devices and medtech, and pharma and therapeutics, with explicit AI focus across the portfolio. The firm’s interest in healthcare is anchored in software and platform companies that build durable infrastructure inside health systems, payers, providers, and life sciences organizations, rather than in pure consumer health or services-heavy plays. Stage focus runs from Series A through Series C and into growth, with the firm building meaningful ownership at A and B and reserving capital for follow-on participation through to growth and crossover rounds. The global footprint is genuinely active rather than nominal; founders building companies with cross-border ambition, particularly across Europe and Asia, will find that Eight Roads has direct operating presence and portfolio reference points in markets where many US-based firms do not.

The specific portfolio detail provided in the source is limited, but Eight Roads has historically been a recognized backer of healthcare technology, enterprise software, and applied AI companies across its three regional footprints. Founders evaluating fit should diligence the current portfolio directly through the firm’s website to understand which categories and stages the firm is most actively deploying into, as the firm’s healthcare emphasis has evolved with the broader maturation of clinical AI and health IT software.

Check sizes typically run between five and twenty-five million dollars, placing Eight Roads firmly in the lead Series A and Series B range with capacity to anchor or co-anchor Series C and growth-stage rounds. The firm prefers to lead or co-lead and to take meaningful board roles. Geographic flexibility is a feature; founders headquartered anywhere across Europe, North America, or Asia can engage credibly, particularly when the company’s plan includes meaningful cross-regional expansion. There is no published hard revenue requirement, but at Series A and beyond, Eight Roads expects credible commercial traction, customer evidence, and a clear path to category leadership.

The firm is partner-driven with regional leadership in London, Boston, and across Asia. Decision-making is structured around the firm’s investment committee, with significant weight given to the regional partner originating the deal. Founders should expect a multi-meeting diligence process, structured engagement with operational and clinical advisors where relevant, and post-investment support that includes board involvement, talent and operating assistance, and downstream introductions to other global investors. The Fidelity heritage gives the firm unusually deep visibility into public-market healthcare and technology trends, which can be particularly valuable for late-stage portfolio companies preparing for crossover or public-market financing.

Warm introductions through existing Eight Roads portfolio CEOs are the most reliable path in, followed by referrals from other top-tier European, US, or Asian Series A and B investors who frequently syndicate with the firm. London-based operators, repeat European founders, and well-known healthcare technology executives are also strong referral sources. Cold inbound is read but converts at lower rates without a specific category or regional angle. A short, sharp memo that establishes category, traction, and the cross-regional dimension of the company’s plan will materially outperform a generic intro.

Founders should approach Eight Roads when the company is at Series A or beyond with credible commercial momentum, when the business is fundamentally a healthcare software, applied-AI, or medtech platform with cross-regional potential, and when there is a genuine ambition to build a category-defining global company. Eight Roads is not the right fit for early-stage seed companies pre-revenue, nor for purely regional plays without cross-border ambition. For the right healthcare AI founder, Eight Roads is one of the few European-headquartered firms that can credibly lead a competitive Series A or B and bring genuine global operational reach to support international scaling.